Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984283 | 0.87 | SLC7A5 (0.38) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL6981261 | 0.86 | SLC7A5 (0.37) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL6582605 | 0.86 | SLC7A5 (0.37) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL6985192 | 0.85 | KMT2A (0.42) | KDM4EKMT2AMEN1HSD17B10LMNA | |
| SCHEMBL6988917 | 0.84 | SLC7A5 (0.36) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL6985172 | 0.84 | AR (0.36) | ELANEKDM4EKMT2AMEN1RECQL | |
| SCHEMBL6984002 | 0.83 | SMN1; SMN2 (0.40) | KDM4EKMT2AMEN1LMNAHPGD | |
| SCHEMBL1282947 | 0.82 | HSD17B10 (0.50) | ELANEKDM4EKMT2AHSD17B10LMNA | |
| SCHEMBL6556774 | 0.82 | ELANE (0.44) | ELANEKDM4EKMT2AMEN1HSD17B10 | |
| SCHEMBL6984974 | 0.81 | SLC6A3 (0.40) | KDM4EKMT2AHSD17B10LMNASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131637-B2 | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| US-6673809-B2 | INHIBITING RESISTANT NEOPLASM, OR NEOPLASM SUSCEPTIBLE TO RESISTANCE | ELI LILLY AND COMPANY | 2004-01-06 | — | — | US | disclosed |
| US-20030216425-A1 | Tricyclic compounds as mrp1-inhibitors | ELI LILLY AND COMPANY | 2003-11-20 | — | — | US | disclosed |
| EP-1301518-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2001096346-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-0390181-A2 | Perylenequinone (UCN-1028D) derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-10-03 | — | — | EP | disclosed |
| US-4863965-A | Ibuprofen acid anhydrides and prodrug pharmaceutical composition containing the same | B.V.B.A. INPHARM (BE) | 1989-09-05 | — | — | US | disclosed |
| EP-0202703-B1 | PHARMACEUTICAL COMPOSITIONS OF THE PRODRUG TYPE, A PROCESS FOR THE PREPARATION THEREOF, A PROCESS FOR THE PREPARATION OF THEM AS PRODRUG FUNCTIONING COMPOUNDS AND COMPOUNDS OBTAINED THEREIN | N.V. Gantax Pharmaceutica (BE) | 1989-08-09 | — | — | EP | disclosed |
| EP-0202703-A1 | Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein | N.V. Gantax Pharmaceutica (BE) | 1986-11-26 | — | — | EP | disclosed |
| EP-0112604-A1 | Novel resolved keto compounds and process | ELI LILLY AND COMPANY (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | ELANE 827/4885KDM4E 2077/4885KMT2A 2090/4885 |
| US-10131637-B2 | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK7, PCSK6 | ELANE 615/4885KDM4E 1134/4885KMT2A 433/4885 |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | ELANE 4513/4885KDM4E 3734/4885KMT2A 2020/4885 |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | ELANE 827/4885KDM4E 2077/4885KMT2A 2090/4885 |
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | ELANE 4558/4885KDM4E 3346/4885KMT2A 1656/4885 |
| US-20030216425-A1 | Tricyclic compounds as mrp1-inhibitors | ABCC1, ABCB1, ABCB11 | ELANE 1698/4885KDM4E 4807/4885KMT2A 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.